Get the Stockscreener App
1.79
1.10%
-0.02
After Hours:
1.80
0.01
+0.56%
Esperion Therapeutics Inc stock is traded at $1.79, with a volume of 9.47M.
It is down -1.10% in the last 24 hours and down -18.64% over the past month.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
See More
Previous Close:
$1.81
Open:
$1.8
24h Volume:
9.47M
Relative Volume:
1.55
Market Cap:
$339.13M
Revenue:
$116.33M
Net Income/Loss:
$-209.25M
P/E Ratio:
-0.8443
EPS:
-2.12
Net Cash Flow:
$-135.49M
1W Performance:
-14.76%
1M Performance:
-18.64%
6M Performance:
-22.51%
1Y Performance:
-16.36%
1-Day Range:
$1.74
$1.825
1-Week Range:
$1.74
$2.13
52-Week Range:
$1.58
$3.94
Esperion Therapeutics Inc Stock (ESPR) Company Profile
Name
Esperion Therapeutics Inc
Sector
Phone
734-887-3903
Address
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Compare ESPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
1.79 | 339.13M | 116.33M | -209.25M | -135.49M | -2.12 |
|
ZTS
Zoetis Inc
|
170.90 | 77.10B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.47 | 42.82B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.39 | 42.45B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.73 | 20.09B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
151.82 | 15.37B | 2.24B | 385.90M | 440.10M | 3.73 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-24 | Initiated | Goldman | Neutral |
| Dec-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-20-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Aug-01-23 | Upgrade | Northland Capital | Under Perform → Market Perform |
| Jun-15-23 | Upgrade | BofA Securities | Underperform → Buy |
| Mar-16-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-16-23 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Mar-07-23 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-27-23 | Resumed | BofA Securities | Neutral |
| Feb-24-23 | Upgrade | Jefferies | Hold → Buy |
| Feb-03-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Aug-03-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| May-05-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Mar-10-22 | Initiated | H.C. Wainwright | Buy |
| Oct-19-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| Oct-14-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| May-05-21 | Downgrade | Stifel | Buy → Hold |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-11-21 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-12-21 | Downgrade | Jefferies | Buy → Hold |
| Feb-09-21 | Downgrade | Goldman | Neutral → Sell |
| Jan-15-21 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-10-20 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-29-20 | Resumed | JP Morgan | Underweight |
| Aug-11-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| Apr-01-20 | Resumed | BofA/Merrill | Buy |
| Mar-17-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-24-20 | Downgrade | Northland Capital | Outperform → Market Perform |
| Feb-14-20 | Downgrade | Citigroup | Buy → Neutral |
| Sep-16-19 | Upgrade | Goldman | Sell → Neutral |
| May-29-19 | Downgrade | Goldman | Neutral → Sell |
| May-06-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Apr-26-19 | Upgrade | Goldman | Sell → Neutral |
| Mar-13-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-07-19 | Reiterated | Needham | Strong Buy |
| Dec-13-18 | Initiated | Goldman | Sell |
| Oct-29-18 | Upgrade | Northland Capital | Market Perform → Outperform |
| Oct-16-18 | Initiated | BTIG Research | Buy |
| Aug-17-18 | Upgrade | Citigroup | Neutral → Buy |
| Jul-11-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-03-18 | Downgrade | JP Morgan | Neutral → Underweight |
| May-02-18 | Downgrade | BofA/Merrill | Buy → Underperform |
View All
Esperion Therapeutics Inc Stock (ESPR) Latest News
Esperion Therapeutics chief commercial officer sells $277 in stock - MSN
What is HC Wainwright’s Estimate for ESPR FY2028 Earnings? - Defense World
Esperion Therapeutics’ (ESPR) Buy Rating Reiterated at HC Wainwright - Defense World
JMP Securities maintains $7 target on Esperion stock - MSN
JMP Securities maintains $7 target on Esperion stock By Investing.com - Investing.com Canada
Esperion Therapeutics' (ESPR) "Market Outperform" Rating Reiterated at JMP Securities - MarketBeat
HC Wainwright Reiterates Buy Rating for Esperion Therapeutics (NASDAQ:ESPR) - MarketBeat
Equities Analysts Set Expectations for ESPR FY2025 Earnings - MarketBeat
Cantor Fitzgerald Comments on ESPR FY2025 Earnings - Defense World
Esperion Therapeutics chief commercial officer sells $277 in stock By Investing.com - Investing.com Australia
Esperion Therapeutics CFO sells shares worth $20 By Investing.com - Investing.com South Africa
Esperion Therapeutics CFO sells shares worth $20 - Investing.com India
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Short Interest Update - MarketBeat
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Stock Position Lifted by Barclays PLC - Defense World
Barclays PLC Grows Position in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat
Esperion stock falls on higher operating expense forecast - MSN
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives $7.30 Consensus Target Price from Analysts - Defense World
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Esperion Therapeutics' (ESPR) Buy Rating Reiterated at HC Wainwright - MarketBeat
IMTX: 3 Small-Cap Healthcare Stocks With Big Upside Potential - StockNews.com
Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET. - The Manila Times
Esperion to Host KOL Event on NEXLETOL, NEXLIZET Real-World Impact in Cholesterol Management - StockTitan
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q2 2024 Earnings Call Transcript - MSN
Geode Capital Management LLC Acquires 171,609 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World
Best 5 Penny Stocks With Great Financial Health (January 2025) - Investing.com
Esperion to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference - The Bakersfield Californian
Esperion to Present at J.P. Morgan Healthcare Conference: Showcasing Non-Statin Breakthroughs - StockTitan
FINAL DEADLINE ALERT: Kaskela Law LLC Announces Shareholder Class Action Lawsuit Against Esperion Therapeutics, Inc. and Encourages Investors with Losses in Excess of $250,000 to Immediately Contact the Firm - AccessWire
Short Interest in Esperion Therapeutics, Inc. (NASDAQ:ESPR) Decreases By 16.5% - MarketBeat
ZTS: 3 Healthcare Innovators with Analyst-Endorsed Upside - StockNews.com
Public Employees Retirement System of Ohio Buys New Position in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat
ESPREsperion Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Wellington Management Group LLP Grows Stock Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat
Analysts Set Expectations for ESPR FY2024 Earnings - Defense World
Cantor Fitzgerald Estimates ESPR FY2024 Earnings - MarketBeat
FOLD: 3 High-Growth Biotech Stocks to Watch - StockNews.com
Esperion Therapeutics CFO Benjamin Halladay sells $7,865 in stock By Investing.com - Investing.com Canada
Esperion Therapeutics CFO Benjamin Halladay sells $7,865 in stock - Investing.com India
Cantor Fitzgerald Initiates Coverage of Esperion Therapeutics (ESPR) with Overweight Recommendation - MSN
Esperion Therapeutics issues $100M in new convertible notes - Investing.com
Esperion Therapeutics issues $100M in new convertible notes By Investing.com - Investing.com UK
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Esperion Therapeutics (NASDAQ:ESPR) Coverage Initiated by Analysts at The Goldman Sachs Group - MarketBeat
Esperion Therapeutics Inc Stock (ESPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.19%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):